Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is a aromatase inhibitor presented as an unknown strength/oral tablet for oral use. It treats postmenopausal estrogen receptor‑positive breast cancer in patients who have completed surgery or radiation and require endocrine therapy.

GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable sourcing for clinical use. Clients benefit from consistent batch release testing and regulatory compliance across EU markets.

Letrozole is used in the endocrine therapy pathway for hormone‑dependent breast cancer. - Postmenopausal early breast cancer: reduces risk of disease recurrence as adjuvant therapy. - Postmenopausal metastatic breast cancer: delays disease progression in advanced disease. - Hormone receptor‑positive breast cancer with ovarian suppression: provides estrogen suppression when combined with ovarian function suppression.

Letrozole may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: transient episodes of increased body temperature. - Joint and muscle pain: mild to moderate musculoskeletal discomfort. - Fatigue: reduced energy levels and increased tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe liver injury: signs of hepatitis or jaundice. - Bone fracture: increased risk due to reduced estrogen. - Pulmonary embolism: sudden shortness of breath and chest pain.

Before initiating Letrozole therapy, consider the following precautions. - Monitor bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Assess liver function: perform periodic liver enzyme tests. - Check cardiovascular status: monitor lipid profile and blood pressure. - Avoid use in patients with known hypersensitivity to letrozole or its excipients. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Letrozole can interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Estrogen replacement therapy: diminishes letrozole efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations.

Moderate Interactions (Monitor Closely): - Tamoxifen: antagonistic effect on estrogen pathways. - Warfarin: may increase INR and bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may alter letrozole metabolism.